Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 27, Number 9—September 2021
Research

Reduction in Antimicrobial Use and Resistance to Salmonella, Campylobacter, and Escherichia coli in Broiler Chickens, Canada, 2013–2019

Laura HuberComments to Author , Agnes Agunos, Sheryl P. Gow, Carolee A. Carson, and Thomas P. Van Boeckel
Author affiliations: Auburn University, Auburn, Alabama, USA (L. Huber); ETH Zürich, Zürich, Switzerland (L. Huber, T.P. Van Boeckel); Public Health Agency of Canada, Guelph, Ontario, Canada (A. Agunos, C.A. Carson); Public Health Agency of Canada, Saskatoon, Saskatchewan, Canada (S.P. Gow); Center for Disease Dynamics, Economics & Policy, Washington, DC, USA (T.P. Van Boeckel)

Main Article

Figure 2

Significant changes (p<0.05) in mean proportion of antimicrobial resistance in Salmonella (A), Escherichia coli (B), and Campylobacter (C) in in broiler chickens, by antimicrobial class, Canada, 2013–2019. Step 1 is the elimination of the preventive use of category I antimicrobials in May 2014 (third-generation cephalosporins and fluoroquinolones) as part of Antimicrobial Use Reduction Strategy stewardship program. Step 2 is the elimination of the preventive use of category II antimicrobials in the end of 2018 (aminoglycosides, lincosamides, macrolides, penicillin, quinolones, streptomycin, and trimethoprim/sulfonamide combinations). Step 3, which was the elimination of the preventive use of category III antimicrobials (e.g., bacitracins and tetracyclines) by the end of 2020, is not represented in the figure. AMC, amoxicillin/clavulanic acid; AMP, ampicillin; CRO, ceftriaxone; FOX, cefoxitin; GEN, gentamycin; NAL, nalidixic acid; STR, streptomycin; TET, tetracycline.

Figure 2. Significant changes (p<0.05) in mean proportion of antimicrobial resistance in Salmonella (A), Escherichia coli (B), and Campylobacter (C) in in broiler chickens, by antimicrobial class, Canada, 2013–2019. Step 1 is the elimination of the preventive use of category I antimicrobials in May 2014 (third-generation cephalosporins and fluoroquinolones) as part of Antimicrobial Use Reduction Strategy stewardship program. Step 2 is the elimination of the preventive use of category II antimicrobials in the end of 2018 (aminoglycosides, lincosamides, macrolides, penicillin, quinolones, streptomycin, and trimethoprim/sulfonamide combinations). Step 3, which was the elimination of the preventive use of category III antimicrobials (e.g., bacitracins and tetracyclines) by the end of 2020, is not represented in the figure. AMC, amoxicillin/clavulanic acid; AMP, ampicillin; CRO, ceftriaxone; FOX, cefoxitin; GEN, gentamycin; NAL, nalidixic acid; STR, streptomycin; TET, tetracycline.

Main Article

Page created: July 14, 2021
Page updated: August 17, 2021
Page reviewed: August 17, 2021
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external